210 related articles for article (PubMed ID: 18225983)
1. Ceftobiprole: a new option for treatment of skin and soft-tissue infections due to methicillin-resistant Staphylococcus aureus.
Widmer AF
Clin Infect Dis; 2008 Mar; 46(5):656-8. PubMed ID: 18225983
[No Abstract] [Full Text] [Related]
2. Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Creech CB; Beekmann SE; Chen Y; Polgreen PM
Pediatr Infect Dis J; 2008 Mar; 27(3):270-2. PubMed ID: 18277924
[TBL] [Abstract][Full Text] [Related]
3. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.
Daum RS
N Engl J Med; 2007 Jul; 357(4):380-90. PubMed ID: 17652653
[No Abstract] [Full Text] [Related]
4. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections.
Fergie J; Purcell K
Pediatr Infect Dis J; 2008 Jan; 27(1):67-8. PubMed ID: 18162942
[No Abstract] [Full Text] [Related]
5. Caution when reconsidering empiric antimicrobial therapy for methicillin-resistant Staphylococcus aureus skin and soft-tissue infections.
da Silva LV; Zavascki AP; de Souza MV; Marcadenti A
Am J Surg; 2008 Oct; 196(4):618-9. PubMed ID: 18809069
[No Abstract] [Full Text] [Related]
6. Emerging drugs for complicated skin and skin-structure infections.
Mendoza N; Tyring SK
Expert Opin Emerg Drugs; 2010 Sep; 15(3):509-20. PubMed ID: 20557269
[TBL] [Abstract][Full Text] [Related]
7. Community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections.
Whitman TJ
Dis Mon; 2008 Dec; 54(12):780-6. PubMed ID: 18996280
[No Abstract] [Full Text] [Related]
8. Epidemiology and treatment of community-associated methicillin-resistant Staphylococcus aureus in children.
Marcinak JF; Frank AL
Expert Rev Anti Infect Ther; 2006 Feb; 4(1):91-100. PubMed ID: 16441212
[TBL] [Abstract][Full Text] [Related]
9. Serious staphylococcal infections--cyclic lipopeptides: meeting new challenges.
Graninger W
Clin Microbiol Infect; 2008 Mar; 14 Suppl 2():1-2. PubMed ID: 18226083
[No Abstract] [Full Text] [Related]
10. Antibiotic options for treating community-acquired MRSA.
Powell JP; Wenzel RP
Expert Rev Anti Infect Ther; 2008 Jun; 6(3):299-307. PubMed ID: 18588495
[TBL] [Abstract][Full Text] [Related]
11. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus.
Stryjewski ME; Chambers HF
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S368-77. PubMed ID: 18462092
[TBL] [Abstract][Full Text] [Related]
12. Drugs for MRSA skin and soft-tissue infections.
Med Lett Drugs Ther; 2014 May; 56(1442):39-40. PubMed ID: 24818839
[No Abstract] [Full Text] [Related]
13. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children.
Frei CR; Makos BR; Daniels KR; Oramasionwu CU
J Pediatr Surg; 2010 Oct; 45(10):1967-74. PubMed ID: 20920714
[TBL] [Abstract][Full Text] [Related]
14. Methicillin-resistant Staphylococcus aureus: an evolving clinical challenge.
Karchmer AW; Bayer AS
Clin Infect Dis; 2008 Jun; 46 Suppl 5():S342-3. PubMed ID: 18462088
[No Abstract] [Full Text] [Related]
15. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections.
Frazee BW; Lynn J; Charlebois ED; Lambert L; Lowery D; Perdreau-Remington F
Ann Emerg Med; 2005 Mar; 45(3):311-20. PubMed ID: 15726056
[TBL] [Abstract][Full Text] [Related]
16. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison--Mississippi, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Oct; 50(42):919-22. PubMed ID: 11699844
[TBL] [Abstract][Full Text] [Related]
17. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus.
Pallin DJ; Egan DJ; Pelletier AJ; Espinola JA; Hooper DC; Camargo CA
Ann Emerg Med; 2008 Mar; 51(3):291-8. PubMed ID: 18222564
[TBL] [Abstract][Full Text] [Related]
18. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA).
Itani KM; Weigelt J; Li JZ; Duttagupta S
Int J Antimicrob Agents; 2005 Dec; 26(6):442-8. PubMed ID: 16289514
[TBL] [Abstract][Full Text] [Related]
19. From the Centers for Disease Control and Prevention. Methicillin-resistant Staphylococcus aureus skin or soft tissue infections in a state prison--Mississippi, 2000.
JAMA; 2002 Jan; 287(2):181-2. PubMed ID: 11799962
[No Abstract] [Full Text] [Related]
20. Treatment of skin and soft tissue infections due to community-associated methicillin-resistant Staphylococcus aureus in Europe: the role of trimethoprim-sulfamethoxazole0010.
De Angelis G; Cipriani M; Cauda R; Tacconelli E
Clin Infect Dis; 2011 Jun; 52(12):1471-2; author reply 1472. PubMed ID: 21628490
[No Abstract] [Full Text] [Related]
[Next] [New Search]
